CLASS ACTION UPDATE for BMRN, CACC and RCL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 22, 2020 /Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BMRN Shareholders Click Here:https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=10395&wire=1
CACC Shareholders Click Here:https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=10395&wire=1
RCL Shareholders Click Here:https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10395&wire=1
* ADDITIONAL INFORMATION BELOW *
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BMRN Lawsuit on behalf of: investors who purchased February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline: November 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=10395&wire=1
According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Credit Acceptance Corporation (NASDAQ:CACC)
CACC Lawsuit on behalf of: investors who purchased November 1, 2019 - August 28, 2020
Lead Plaintiff Deadline: December 1, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=10395&wire=1
According to the filed complaint, during the class period, Credit Acceptance Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (ii) Credit Acceptance was making high-interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (iii) the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (iv) Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (v) as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (vi) that, as a result of the foregoing, Defendants positive statements about the Company's business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.
Royal Caribbean Cruises Ltd. (NYSE:RCL)
RCL Lawsuit on behalf of: investors who purchased February 4, 2020 - March 17, 2020
Lead Plaintiff Deadline: December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10395&wire=1
According to the filed complaint, during the class period, Royal Caribbean Cruises Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE:Levi & Korsinsky, LLP
View source version on accesswire.com:
© 2020 Accesswire. All Rights Reserved.